Eukaryotic cells expressing at their surface at least an hla-g isoform and their applications
CA 2251645 A1 · Owner: Carosella, Edgardo Delfino · Inventors: Carosella, Edgardo Delfino; Dausset, Jean; Rouas-Freiss, Nathalie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the use of a eukaryotic cell coding for at least an HLA-G isoform to obtain an immunomodulating medicine for inhibiting the activity of killer cells in particular NK cells and/or for inhibiting the primary allogenic response in pathologies or situations in which the killer cells are activated or for preparing a medicine to raise the inhibiting function of the isoform(s) expressed by said cells with respect to killer cells in particular NK cells, in pathologies where these killer cells are inhibited by the molecule of the major histocompatibility complex of I HLA-G classes. The invention also concerns eukaryotic cells expressing at their surface at least an HLA-G …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 20, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.